Interleukin-6 and prostate cancer progression

被引：227

作者：

Smith, PC

Hobisch, A

Lin, DL

Culig, Z

Keller, ET

机构：

[1] Univ Michigan, Inst Gerontol, Unit Lab Anim Med, Ann Arbor, MI 48109 USA

[2] Univ Michigan, Connect Tissue Oncol Program, Ann Arbor, MI 48109 USA

[3] Univ Innsbruck, Dept Urol, A-6020 Innsbruck, Austria

来源：

CYTOKINE & GROWTH FACTOR REVIEWS | 2001年 / 12卷 / 01期

关键词：

cytokine; androgen receptor; signal transduction; chemotherapy; androgen independence;

D O I：

10.1016/S1359-6101(00)00021-6

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Prostate cancer, while initially dependent on androgens fbr proliferation, progresses to an androgen-independent state. Evidence has been accumulating that interleukin-6 (IL-6) may contribute to prostate cancer progression. Serum levels of IL-6 correlate with prostate tumor burden and patient morbidity. The prostate tissue itself appears to be a source of IL-6 and its receptor. Furthermore, experimental data suggest that IL-6 is an autocrine and paracrine growth factor for androgen-independent prostate cancer cell lines. For example, inhibition of IL-6, with anti-IL-6 antibody, sensitizes androgen-independent prostate cancer cells to chemotherapeutic agents in vitro. Finally, IL-6 activates a variety of signal transduction cascades, some which stimulate androgen receptor activity, in prostate cancer cells. These data suggest that targeting IL-6 may have multiple benefits in prostate cancer patients. (C) 2001 Elsevier Science Ltd. All rights reserved.

引用

页码：33 / 40

页数：8

共 92 条

[1] Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma [J].